MIM
ZBIO

MetLife Investment Management’s Zenas BioPharma ZBIO Stock Holding History

MetLife Investment Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Buy
12,909
+2,809
+28% +$63.1K ﹤0.01% 2106
2025
Q4 		$367K Hold
10,100
– – ﹤0.01% 1940
2025
Q3 		$224K Hold
10,100
– – ﹤0.01% 2254
2025
Q2 		$97.9K Buy
10,100
+13
+0.1% +$127 ﹤0.01% 2552
2025
Q1 		$79.7K Sell
10,087
-138
-1% -$1.08K ﹤0.01% 2614
2024
Q4 		$83.7K Buy
+10,225
New +$159K ﹤0.01% 2683

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

MetLife Investment Management's ZBIO Position: Q1 2026 in Review

MetLife Investment Management increased its Zenas BioPharma (ZBIO) stake by 28% in Q1 2026, buying an estimated $63.1K and bringing the position to 12,909 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2106.

MetLife Investment Management first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $367K in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • MetLife Investment Management held 12,909 shares of Zenas BioPharma worth $252K as of Q1 2026.
  • MetLife Investment Management bought 2,809 Zenas BioPharma shares in Q1 2026, an estimated $63.1K.
  • Zenas BioPharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2106 holding.
  • MetLife Investment Management first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • MetLife Investment Management's Zenas BioPharma position peaked at $367K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.